Compare MSBI & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSBI | ASMB |
|---|---|---|
| Founded | 1881 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.2M | 499.8M |
| IPO Year | 2016 | 2010 |
| Metric | MSBI | ASMB |
|---|---|---|
| Price | $23.89 | $26.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $22.83 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 186.4K | 105.8K |
| Earning Date | 01-22-2026 | 03-19-2026 |
| Dividend Yield | ★ 5.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $210,718,000.00 | $37,191,000.00 |
| Revenue This Year | $28.14 | $33.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.30 |
| 52 Week Low | $14.24 | $7.75 |
| 52 Week High | $24.57 | $39.71 |
| Indicator | MSBI | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 71.15 | 40.79 |
| Support Level | $22.43 | $24.68 |
| Resistance Level | $23.22 | $28.64 |
| Average True Range (ATR) | 0.72 | 1.81 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 81.79 | 30.32 |
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.